The company plans to develop tests for prostate cancer risk assessment, prostate cancer screening, and breast cancer screening.
The approach, published earlier this week in Nature Biomedical Engineering, uses long-adapter single-strand oligonucleotide (LASSO) probes.
Hopkins' Geoffrey Ling discusses the promise of genomic vaccines at Scientific American.
At the WIN Symposium, a Merck executive detailed how data from a basket study led to the first pan-cancer, biomarker-informed cancer drug.
In 86 pretreated cancer patients with mismatch repair deficiency, researchers saw objective response rates exceeding 50 percent after anti-PD-1 immunotherapy.
Qiagen will use NGS to develop gene expression profiles related to BMS immuno-oncology therapies; and the company has licensed IO therapy response biomarkers from JHU.
Researchers used exome and targeted sequencing to find alterations affecting KRAS and other cancer driver genes in a subset of deep infiltrating endometriosis samples.
John Littlefield, a pediatrician and geneticist, has died, the Baltimore Sun reports.
Johns Hopkins University researchers have developed a method called targeted error correction sequencing, or TEC-Seq, to increase liquid biopsy sensitivity.
Such analyses can help researchers pinpoint how various cancers evolve and determine the best kinds of tests to use to find certain disease information.
A genetic genealogy analysis helped secure the release of a California man from prison after getting his murder conviction overturned, the Guardian reports.
Technology Review discusses the concerns that come along with the ability to quickly synthesize viruses like SARS-CoV-2.
Researchers have uncovered large bacteriophages whose genomes include translational machinery, Live Science reports.
In PNAS this week: role for Myc in alternative splicing regulation in prostate cancer, variation in methylation in Arabidopsis, and more.